Navigation Links
Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
Date:10/29/2008

Franklin's Experience to Bring Growth and Leadership

CARY, N.C., Oct. 29 /PRNewswire/ -- Cornerstone Therapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today announced that Josh Franklin has joined the company as vice president, Marketing.

Craig Collard, Cornerstone's president and chief executive officer, welcomed Franklin to the company, noting that "Josh's skills in pharmaceutical brand management and his leadership experience in a growth environment will be key as Cornerstone transitions into a publicly-held company." As announced in May Cornerstone plans to go public through a merger with Critical Therapeutics (Nasdaq: CRTX), which is scheduled to close in Q4 2008.

Before his Cornerstone appointment, Franklin was a key member of the marketing team at St. Louis, Mo.-based Ther-Rx Corporation (a subsidiary of KV Pharmaceutical) during a critical five-year growth period, serving most recently as vice president, Marketing. In previous positions, Franklin filled marketing roles with Biovail Pharmaceuticals and Ross Products Division, Abbott Labs. In these positions, he launched and managed products throughout various lifecycle phases in multiple therapeutic categories.

"I know I'm joining Cornerstone at a pivotal time," said Franklin, returning to North Carolina for the second time in his career. "And, I'm looking forward to helping lead not only the evolution of products and processes but also the company itself as our organization elevates to the next level."

A U.S. Army veteran, Mr. Franklin holds a B.S. in Business Administration from Methodist University, and M.H.A. and M.B.A. degrees from The Ohio State University.

ABOUT CORNERSTONE THERAPEUTICS, INC.

Cornerstone BioPharma Holdings, Inc., located in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. Cornerstone currently promotes four marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone's commercial strategy is to acquire non-promoted or underperforming branded pharmaceutical products and then maximize their potential value by promoting the products using its sales and marketing capabilities and applying various product life cycle management techniques. Cornerstone's product development pipeline consists of three line extensions of one of its currently marketed products and three other product candidates for the respiratory market. Cornerstone also generates revenue from the sale of six marketed product lines that include products that it does not promote.


'/>"/>
SOURCE Cornerstone Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
5. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
6. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
7. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
8. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
9. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
10. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
11. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... (PRWEB) , ... April 30, 2017 , ... PracticeMatch, a ... increase in projected attendance for this year’s physician career fairs, with this year’s RSVPs ... complete schedule for the 2017 calendar year of national physician career fairs is located ...
(Date:4/29/2017)... S.C. (PRWEB) , ... April ... ... Southeast’s leading software and web development company, today announced the launch of ... DonorBridge is a solution combining decades of software innovation and industry expertise ...
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/29/2017)... ... April 29, 2017 , ... Sterling Global Products ... fine retailers selling biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs ... in San Antonio, Texas, operates more than 350 stores throughout Texas and expanding ...
(Date:4/29/2017)... ... April 29, 2017 , ... ... and recognize the positive impact veterinarians have on animal health and welfare as ... Organization for Animal Health (OIE) choose a theme each year and this year ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... Halo Labs announces the launch of a ... called the Horizon at PEGS 2017 in ... analyzes sub visible particulate matter in biopharmaceutical samples to ... early as candidate selection and pre-formulation. Halo ... organization Elion Labs for system validation. "We ...
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
Breaking Medicine Technology: